A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas

A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas

Rhabdomyosarcomas are the most common pediatric soft tissue sarcoma and are a major cause of death from cancer in young patients requiring new treatment options to improve outcomes. High-risk patients include those with metastatic or relapsed disease and tumors with PAX3-FOXO1 fusion genes that enco...

Full description

Bibliographic Details
Main Authors: Susanne A. Gatz, Ewa Aladowicz, Michela Casanova, Julia C. Chisholm, Pamela R. Kearns, Simone Fulda, Birgit Geoerger, Beat W. Schäfer, Janet M. Shipley
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
polo-like kinase 1
PLK1 inhibitors
rhabdomyosarcomas
combination treatment
microtubule disruptors
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01271/full

Similar Items

Similar Items